Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD)

Gene Therapy

Volumn 11, Issue , 2004, Pages S109-S121

  Athanasopoulos, T ^a   Graham, I R ^a   Foster, H ^a   Dickson, G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AAV; DMD; Microdystrophin; Muscle; Virus

Indexed keywords

BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; DYSTROPHIN; MESSENGER RNA; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT CHORIONIC GONADOTROPIN; VASCULOTROPIN;

BECKER MUSCULAR DYSTROPHY; CELL GROWTH; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; GENE CASSETTE; GENE TARGETING; GENETIC DISORDER; GENETIC TRANSDUCTION; GENOTYPE PHENOTYPE CORRELATION; HEART MUSCLE; HUMAN; IMMUNOGENICITY; MOLECULAR SIZE; MUSCLE CELL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; SKELETAL MUSCLE; SPECIES DIFFERENCE; TISSUE GROWTH; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINATION; VIRUS VIRULENCE;

ANIMALS; DEPENDOVIRUS; DYSTROPHIN; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED MDX; MODELS, ANIMAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM;

EID: 5444275698     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302379     Document Type: Review

References (152)

1. Acsadi G et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991; 352: 815-818.
2. Chamberlain JS. Gene Therapy of muscular dystrophy. Hum Mol Genet 2002; 11: 2355-2362.
3. Hartigan-O'Connor D, Chamberlain JS. Developments in gene therapy for muscular dystrophy. Microsc Res Technol 2000; 48: 223-238.
4. Lynch GS, Rafael JA, Chamberlain JS, Faulkner JA. Contraction- induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. Am J Physiol Cell Physiol 2000; 279: C1290-C1294.
5. DelloRusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction- induced injury. J Muscle Res Cell Motil 2001; 22: 467-475.
6. Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001; 24: 1575-1594.
7. Rafael JA et al. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum Mol Genet 2000; 9: 1357-1367.
8. Friedrich O et al. Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. J Physiol (Lond) 2004; 555: 251-265.
9. Lynch GS et al. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol (Lond) 2001; 535: 591-600.
10. Cox GA et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993; 364: 725-729.
11. Chamberlain JS. Dystrophin levels required for genetic correction of Duchenne muscular dystrophy. Basic Appl Myol 1997; 7: 251-255.
12. Athanasopoulos T, Fabb S, Dickson G. Gene therapy. vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases [Review]. Int J Mol Med 2000; 6: 363-375.
13. Buning H et al. AAV-based gene transfer. Curr Opin Mol Ther 2003; 5: 367-375.
14. Buning H et al. Receptor targeting of adeno-associated virus vectors. Gene Therapy 2003; 10: 1142-1151.
15. Chao H et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999; 6: 1695-1704.
16. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy - a review. Stem Cells Dev 2003; 13: 133-145.
17. Cordier L et al. Rescue of skeletal muscles of gamma- sarcoglycan-deficient mice with adeno-associated virusmediated gene transfer. Mol Ther 2000; 1: 119-129.
18. Snyder RO et al. Efficient and stable adeno-associated virusmediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
19. Xiao X et al. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy J Virol 2000; 74: 1436-1442.
20. Abadie J et al. Recombinant adeno-associated virus type 2 mediates highly efficient gene transfer in regenerating rat skeletal muscle. Gene Therapy 2002; 9: 1037-1043.
21. Chao HJ et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-623.
22. Arruda VR et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004; 103: 85-92.
23. Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
24. Hauck B, Xiao WD. Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 2003; 77: 2768-2774.
25. Hildinger M et al. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199-6203.
26. Xiao WD et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
27. Rabinowitz JE et al. Cross-packaging of a single adeno- associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
28. Bantel-Schaal U, Delius H, Schmidt R, zur Hausen H. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol 1999; 73: 939-947.
29. Walters RW et al. Binding of adeno-associated virus type 5 to 2, 3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276: 20610-20616.
30. Duan DS et al. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol 2001; 75: 7662-7671.
31. Bowles DE, Rabinowitz JE, Samulski RJ. Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol 2003; 77: 423-432.
32. Hauck B, Chen L, Xiao WD. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 2003; 7: 419-425.
33. DelloRusso C et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 2002; 99: 12979-12984.
34. Bies RD et al. Human and murine dystrophin messenger-RNA transcripts are differentially expressed during skeletal-muscle, heart, and brain development. Nucleic Acids Res 1992; 20: 1725-1731.
35. Corrado K, Mills PL, Chamberlain JS. Deletion analysis of the dystrophin-actin binding domain. FEBS Lett 1994; 344: 255-260.
36. Corrado K et al. Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a 'mild becker' phenotype. J Cell Biol 1996; 134: 873-884.
37. Crawford GE et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH- terminal domain. J Cell Biol 2000; 150: 1399-1410.
38. Crawford GE, Lu QL, Partridge TA, Chamberlain JS. Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Hum Mol Genet 2001; 10: 2745-2750.
39. Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opin Biol Ther 2003; 3: 803-814.
40. Ahmad A et al. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet 2000; 9: 2507-2515.
41. Decrouy A et al. Mini-dystrophin gene transfer in mdx 4(cv) diaphragm muscle fibers increases sarcolemmal stability. Gene Therapy 1997; 4: 401-408.
42. Roberts ML, Dickson G. The future of Duchenne muscular dystrophy gene therapy: Shrinking the dystrophin gene. Curr Opin Mol Ther 2002; 4: 343-348.
43. Sakamoto M et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293: 1265-1272.
44. Wells DJ, Wells KE. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? Neuromuscular Disord 2002; 12: S11-S22.
45. Decrouy A et al. Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4(cv) skeletal muscle fibers. Gene Therapy 1998; 5: 59-64.
46. Dickson G, Roberts ML, Wells DJ, Fabb SA. Recombinant micro-genes and dystrophin viral vectors. Neuromuscular Disord 2002; 12: S40-S44.
47. Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a kDa micro-dystrophin effectively restores the dystrophin- associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 2002; 11: 733-741.
48. Harper SQ, Crawford RW, DelloRusso C, Chamberlain JS. Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Hum Mol Genet 2002; 11: 1807-1815.
49. Harper SQ et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253-261.
50. Yuasa K et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Therapy 2002; 9: 1576-1588.
51. Clemens PR et al. Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy families, using dinucleotide repeat polymorphisms. Am J Hum Genet 1991; 49: 951-960.
52. Watchko J et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 2002; 13: 1451-1460.
53. Xiao X et al. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74: 1436-1442.
54. Li S et al. Muscle-specific enhancement of gene expression by incorporation of SV/40 enhancer in the expression plasmid. Gene Therapy 2001; 8: 494-497.
55. Scott JM et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscular Disord 2002; 12: S23-S29.
56. Cordier L et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205-215.
57. Yue YP, Duan DS. Development of multiple cloning site cis- vectors for recombinant adeno-associated virus production. Biotechniques 2002; 33: 672-675.
58. Xu LF et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
59. Larochelle N et al. The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice. Biochem Biophys Res Commun 2002; 292: 626-631.
60. Dunant P et al. Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice. Mol Ther 2003; 8: 80-89.
61. Hagstrom JN et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 2000; 95: 2536-2542.
62. Haberman RP, Mccown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000; 74: 8732-8739.
63. Hartigan-O'Connor D et al. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
64. Phelps SF et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-1258.
65. Draghia-Akli R et al. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol 1999; 17: 1179-1183.
66. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999; 17: 241-245.
67. Phillips MI et al. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 2002; 39: 651-655.
68. Sun LW, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6: 599-602.
69. Yan ZY, Zhang YL, Duan DS, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000; 97: 6716-6721.
70. Yan ZY, Ritchie YC, Duan DS, Engelhardt JF. Recombinant AAV-mediated gene delivery using dual vector heterodi- merization. Gen Ther Methods 2002; 346: 334-357.
71. Yang JS et al. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73: 9468-9477.
72. Duan DS, Yue YP, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001; 4: 383-391.
73. Samulski RJ. Expanding the AAV package. Nat Biotechnol 2000; 18: 497-498.
74. Yue YP, Duan DS. Double strand interaction is the predominant pathway for intermolecular recombination of adeno-associated viral genomes. Virology 2003; 313: 1-7.
75. Chenuaud P et al. Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 2004; 9: 410-418.
76. van Deutekom JCT et al. Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscular Disord 1998; 8:135-148.
77. Work LM et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198-208.
78. Svensson EC et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999; 99: 201-205.
79. Vassalli G et al. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol 2003; 90: 229-238.
80. Asfour B et al. Uniform long-term gene expression using adeno- associated virus (AAV) by ex vivo recirculation in rat-cardiac isografts. Thor Cardiov Sur 2002; 50: 347-350.
81. Hoshijima M et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864-871.
82. Li J et al. Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gen Therapy 2003; 10: 1807-1813.
83. Yue YP et al. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003; 108: 1626-1632.
84. Davis HL, Jasmin BJ. Direct gene transfer into mouse diaphragm. FEBS Lett 1993; 333: 146-150.
85. Decrouy A et al. Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability. Gene Therapy 1997; 4: 401-408.
86. Feng L, Makiya N, Clemens PR, Huang L. Transfer of full- length dmd to the diaphragm muscle of dmd mdx/md mice through systemic administration of plasmid DNA. Mol Ther 2001; 4: 45-51.
87. Mah C et al. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther 2004; 9: 458-463.
88. Pruchnic R et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther 2000; 11: 521-536.
89. Chang DS et al. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 2003; 7: 44-51.
90. Donahue BA et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J Gene Med 1999; 1: 31-42.
91. Auricchio A et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110: 499-504.
92. Aubert D et al. Cytotoxic immune response after retroviral- mediated hepatic gene transfer in rat does not preclude expression from adeno-associated virus 1 transduced muscles. Hum Gene Ther 2003; 14: 473-481.
93. Blankinship MJ et al. Progress toward gene therapy of Duchenne muscular dystrophy using truncated four-repeat dystrophin and AAV6. J Neurol Sci 2002; 199: 01-05.
94. Blouin V et al. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6: S223-S228.
95. Grimm D et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-2419.
96. Harding TC et al. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Therapy 2004; 11: 204-213.
97. Ponnazhagan S et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
98. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75: 6615-6624.
99. Lipshutz GS et al. In utero delivery of adeno-associated viral vectors: Intraperitoneal gene transfer produces long-term expression. Mol Ther 2001; 3: 284-292.
100. Bouchard S et al. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice. J Gene Med 2003; 5: 941-950.
101. Mitchell M et al. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Therapy 2000; 7: 1986-1992.
102. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). JMed Virol 1999; 59: 406-411.
103. Wang CH et al. Can genes transduced by adeno-associated virus vectors elicit or evade an immune response? Arch Virol 2004; 149: 1-15.
104. Xin KQ et al. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J Gene Med 2003; 5: 438-445.
105. Xiao WD et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1: 323-329.
106. Brockstedt DG et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 92: 67-75.
107. Zhang Y, Chirmule N, Gao GP, Wilson J. CD40 ligand- dependent activation of cytotoxic T lymphocytes by adeno- associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74: 8003-8010.
108. Chirmule N et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
109. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733-3737.
110. Manno CS et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
111. Arruda VR et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001; 4: 586-592.
112. Jooss K, Yang YP, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
113. Hernandez YJ et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73: 8549-8558.
114. Herzog RW et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13: 1281-1291.
115. Sarukhan A et al. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001; 75: 269-277.
116. Dressman D et al. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther 2002; 13: 1631-1646.
117. Ferrer A, Wells KE, Wells DJ. Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Gene Therapy 2000; 7: 1439-1446.
118. Manning WC et al. Transient immunosuppression allows transgene expression following readministration of adeno- associated viral vectors. Hum Gene Ther 1998; 9: 477-485.
119. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA 2000; 97: 4862-4866.
120. Duan DS et al. Circular intermediates of recombinant adeno- associated virus have defined structural characteristics responsible for long- term episomal persistence in muscle tissue. J Virol 1998; 72: 8568-8577.
121. Duan DS, Yan ZY, Yue YP, Engelhardt JF. Structural analysis of adeno-associated virus transduction circular intermediates. Virology 1999; 26: 8-14.
122. Vincent-Lacaze N et al. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73: 1949-1955.
123. Russell DW. AAV loves an active genome. Nat Genet 2003; 34: 241-242.
124. Pachori AS et al. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun 2004; 313: 528-533.
125. Couto L, Parker A, Gordon JW. Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno- associated virus vector fails to lead to germ cell transduction. Hum Gene Ther 2004; 15: 287-291.
126. Schnepp BC et al. Genetic fate of recombinant adeno- associated virus vector genomes in muscle. J Virol 2003; 77: 3495-3504.
127. McCarty DM et al. Identification of linear sequences that specifically bind the adeno-associated virus Rep protein. J Virol 1994; 68: 4988-4997.
128. Megeney LA et al. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999; 96: 220-225.
129. Nakamura A et al. Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett 2002; 520: 18-24.
130. Deconinck AE et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90: 717-727.
131. Ding Z et al. A minimally invasive approach for efficient gene delivery to rodent hearts. Gene Therapy 2004; 11: 260-265.
132. Greelish JP et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated vector. Nat Med 1999; 5: 439-443.
133. Zhang G et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Therapy 2004; 11: 675-682.
134. Crosbie RH et al. Characterization of aquaporin-4 in muscle and muscular dystrophy. FASEB J 2002; 16: 943-949.
135. Zhang YC et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Therapy 2004; 11: 233-240.
136. Wright JF, Qu G, Tang CL, Sommer JM. Recombinant adeno- associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Dev 2003; 6: 174-178.
137. Liu YL et al. Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques 2003; 34: 184-188.
138. Sollerbrant K et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001; 82: 2051-2060.
139. Urabe M, Ding CT, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-1943.
140. Whiteway A, Deru W, Prentice HG, Anderson R. Construction of adeno-associated virus packaging plasmids and cells that directly select for AAV helper functions. J Virol Methods 2003; 114: 1-10.
141. Zolotukhin S et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167.
142. Gao GP et al. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 2000; 11: 2079-2091.
143. Grimm D. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 2002; 28: 146-157.
144. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7: 839-850.
145. Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 2002; 13: 1235-1243.
146. O'Riordan CR, Lachapelle AL, Vincent KA, Wadsworth SC. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gen Med 2000; 2: 444-454.
147. Smith RH, Ding CT, Kotin RM. Serum-free production and column purification of adeno-associated virus type 5. J Virol Methods 2003; 114: 115-124.
148. Wright VJ, Peng HR, Huard J. Muscle-based gene therapy and tissue engineering for the musculoskeletal system. Drug Discov Today 2001; 6: 728-733.
149. Arakawa M et al. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 2003; 134: 751-758.
150. Ferrer A et al. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene Therapy 2004; 11: 884-893.
151. Gregorevic P et al. Systematic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834.
152. Kaiser J. Side effects sideline hemophilia trial. Science 2004; 304: 1423-1424.